Treatment For Chronic Hepatitis C: A Phase II Study
Links shared publicly online about this topic.
- 1,447total visits
Treatment For Chronic Hepatitis C: A Phase II Study
View full resource at medicalnewstoday.com
Tags: Liver Condition, Hepatitis, Hepatitis C, Hepatitis C Medication, Rebetol
Most Recently Shared on January 18, 2010 at 2:13 pm By:
Treatment For Chronic Hepatitis C: A Phase II Study http://mnt.to/3wrN
Vertex initiates INCIVEK combination Phase 3b study for hepatitis C
news-medical.net — “Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called CONCISE that will evaluate the potential for treatment with INCIVEK (telaprevir) combination therapy to be shortened to 12 weeks in people with genotype 1 chronic hepatitis C who have the 'CC' variation near the IL28B gene.” View full resource at news-medical.net
Most Recently Shared on October 24, 2011 at 4:42 pm By:
Epilepsy News: Vertex initiates INCIVEK combination Phase 3b study for hepatitis C: Vertex Pharmaceuticals Incor... http://t.co/OC7pV0Ib
Hepatitis and Liver Health - Hepatitis News : Hep C Drug Development Pipeline is “Robust,” Says Report
hepmag.com — “The hepatitis C virus (HCV) drug development pipeline is robust, with numerous agents in Phase II or III studies, and several promising compounds in Phase I clinical trials, according to an optimistic report produced by U.K.-based i-Base in collaboration with U.S.-based Treatment Action Group (TAG).” View full resource at hepmag.com
Most Recently Shared on July 20, 2011 at 12:00 am By:
Regan Hofmann Health Communicator
RT @hepatitismag: Hepatitis News : Hep C Drug Development Pipeline is “Robust,” Says Report http://ow.ly/5HjoC #Hepatitis #HCV #HepC
Telaprevir-Based Regimens More Effective Than Current Standard Of Treatment In Curing Genotype 1 HCV Patients
medicalnewstoday.com — “Data from two Phase 3 telaprevir clinical trials for chronic genotype 1 hepatitis C (HCV), ADVANCE and REALIZE, has been published in the New England Journal of Medicine. The studies show that tre” View full resource at medicalnewstoday.com
Most Recently Shared on June 26, 2011 at 7:05 am By:
Telaprevir-Based Regimens More Effective Than Current Standard Of Treatment In Curing Genotype 1 HCV Patients http://mnt.to/3XFL
New England Journal of Medicine Publishes Data From Two Phase 3 Studies of Incivek (telaprevir) in Hepatitis C - Drugs.com MedNews
drugs.com — “-INCIVEK was recently approved by the FDA and is now available for people with the most common form of chronic hepatitis C who are new to treatment and those wh” View full resource at drugs.com
Most Recently Shared on June 23, 2011 at 3:09 pm By:
Drugs and Devices OW OW Health
New England Journal of Medicine Publishes Data From Two Phase 3 Studies of Incivek (telaprevir) in Hepatit... http://bit.ly/lPadl7 #drug
Family Medicine Article | Hepatitis C
mdlinx.com — “Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: A phase 1b multiple ascending dose study” View full resource at mdlinx.com
Most Recently Shared on May 21, 2011 at 7:29 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/R... http://bit.ly/m4sUNm #FamPractice
Gastroenterology Article | Hepatitis C
mdlinx.com — “Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: A phase 1b multiple ascending dose study” View full resource at mdlinx.com
Most Recently Shared on May 20, 2011 at 10:42 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) le... http://bit.ly/kc3DIB #GI
Medivir reports positive results from ASPIRE TMC435 phase 2b study for genotype 1 chronic hepatitis C
news-medical.net — “Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announced results from the ASPIRE phase 2b study that evaluates the addition of once daily TMC435 to pegylated interferon and ribavirin in patients with genotype 1 chronic hepatitis C whose prior treatment with pegylated-interferon (PegIFN) and ribavirin (RBV) was unsuccessful either because they relapsed, had a partial response or had a null response.” View full resource at news-medical.net
Most Recently Shared on May 20, 2011 at 10:08 am By:
Medivir reports positive results from ASPIRE TMC435 phase 2b study for genotype 1 chronic hepatitis C: Medivir A... http://bit.ly/lVHORn
'Victrelis'™ Added To Peginterferon Alfa-2a And Ribavirin Gives Higher Cure Rates In Treatment-Failure Patients With Chronic HCV Genotype 1
medicalnewstoday.com — “MSD reported that final results from a Phase III study of 'Victrelis'™ (boceprevir), its investigational oral hepatitis C protease inhibitor, added to peginterferon alfa-2a ('Pegasys'®)” View full resource at medicalnewstoday.com
Most Recently Shared on April 1, 2011 at 11:05 pm By:
'Victrelis'™ Added To Peginterferon Alfa-2a And Ribavirin Gives Higher Cure Rates In Treatment-Failure Patients ... http://mnt.to/3T54
Transgene Announces Completion Of Enrolment In HCVac (Phase II Trial) Of TG4040 For The Treatment Of Chronic Hepatitis C
medicalnewstoday.com — “Transgene S.A. (Paris:TNG)(Euronext Paris: FR0005175080) announces that, with 154 patients randomized and treated, the enrolment of patients in the phase II HCVac trial is now complete. This study” View full resource at medicalnewstoday.com
Most Recently Shared on April 1, 2011 at 9:05 am By:
MNT Clinical Trials Health News
Transgene Announces Completion Of Enrolment In HCVac (Phase II Trial) Of TG4040 For The Treatment Of Chronic Hepatitis C http://mnt.to/3T3r
Vertex announces final results from Phase 3 REALIZE study against HCV
news-medical.net — “Vertex Pharmaceuticals Incorporated today announced final results from its pivotal Phase 3 REALIZE study that evaluated people with genotype 1 chronic hepatitis C whose prior treatment with pegylated-interferon and ribavirin was unsuccessful either because they relapsed, had a partial response or had a null response.” View full resource at news-medical.net
Most Recently Shared on April 1, 2011 at 7:30 am By:
Epilepsy News: Vertex announces final results from Phase 3 REALIZE study against HCV: Vertex Pharmaceuticals Inc... http://bit.ly/dEIrPp
Novartis first-in-class antiviral DEB025 achieved sustained viral response in 76% of patients with chronic hepatitis C, new phase II study shows - Drugs.com MedNews
drugs.com — “DEB025 plus standard of care (pegylated-interferon alfa 2a ribavirin) showed superior viral cure vs standard of care alone (p 0.008) 1 A cyclophilin inhibitor,” View full resource at drugs.com
Most Recently Shared on March 31, 2011 at 9:17 pm By:
Drugs and Devices OW OW Health
Novartis first-in-class antiviral DEB025 achieved sustained viral response in 76% of patients with chronic... http://bit.ly/g9PdB0 #drug
Investigational Direct-Acting Antiviral BMS-790052 Plus PEG-Interferon Alfa and Ribavirin Achieved Up to 92% Sustained Virologic Response in Phase II Dose-Ranging Study of Treatment-Naïve Hepatitis C Patients - Drugs.com MedNews
drugs.com — “Adverse event profile of regimen containing BMS-790052 was consistent with that of treatment with PEG-Interferon alfa and ribavirin alone Mar 31, 2011 - Bristol” View full resource at drugs.com
Most Recently Shared on March 31, 2011 at 5:13 pm By:
Drugs and Devices OW OW Health
Investigational Direct-Acting Antiviral BMS-790052 Plus PEG-Interferon Alfa and Ribavirin Achieved Up to 9... http://bit.ly/gWyUv2 #drug
Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C
news-medical.net — “Vertex Pharmaceuticals Incorporated today announced interim results from an ongoing Phase 2 study designed to assess the safety and tolerability of 12-week response-guided treatment regimens with its polymerase inhibitor, VX-222, and its protease inhibitor, telaprevir, in combination with pegylated-interferon and ribavirin in people with genotype 1 chronic hepatitis C who were new to treatment.” View full resource at news-medical.net
Most Recently Shared on March 31, 2011 at 11:29 am By:
Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C: Vertex Pharmaceuticals I... http://bit.ly/gOV0JW
Tibotec Starts Global Phase 3 Clinical Trials Studying TMC435 In Adults With Chronic Genotype 1 HCV
medicalnewstoday.com — “Tibotec Pharmaceuticals announced that two global, registrational phase 3 trials are recruiting patients to examine TMC435, its investigational hepatitis C protease inhibitor, in treatment-nave” View full resource at medicalnewstoday.com
Most Recently Shared on February 21, 2011 at 1:05 pm By:
Tibotec Starts Global Phase 3 Clinical Trials Studying TMC435 In Adults With Chronic Genotype 1 HCV http://mnt.to/3Rnp #liver #hepatitis
Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010
news-medical.net — “Gilead Sciences, Inc. today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the four-year efficacy of Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection.” View full resource at news-medical.net
Most Recently Shared on November 1, 2010 at 10:36 am By:
HIV/AIDS News: Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The ... http://bit.ly/9mkzyC
Advertisement
